DuPont de Nemours reports Q2 results on August 4 with options traders the most bullish they have been in months — a notable divergence from the cautious tone that has characterised the specialty chemicals sector this summer.
The options market is leaning decisively toward the upside. The put/call ratio dropped to 0.48 on July 31, roughly one standard deviation below its 20-day average of 0.59 — the lowest defensive posture DD options have shown in recent weeks. That call-heavy tilt suggests traders are positioning for a positive surprise rather than hedging against a miss. The stock itself has been essentially flat on the week at $137.00, having clawed back most of a modest month-long dip, and the lending market offers no countervailing bearish signal: availability runs above 1,100% of outstanding short interest, meaning borrow is abundant and cost to borrow a negligible 0.37%. Short interest at just over 1% of the free float — and down 25% over the past week — tells a story of bears retreating, not pressing.
The bull and bear cases for DuPont are well-defined heading into the print. Bulls point to sustained momentum in Healthcare and Water, where high-single-digit sales growth in medical packaging and biopharma solutions has driven the stock 14.5% higher year-to-date. The Electronics & Industrial segment, meanwhile, is seen as a long-term beneficiary of 5G and IoT build-out. Against that, bears flag the pace of post-merger synergy realisation, lingering weakness in construction-adjacent demand, and a China recovery that remains uneven. The analyst community has gently tilted bullish — Citigroup raised its target to $170 in early July while maintaining a Buy rating — and the consensus price target of $169.50 implies around 24% upside from current levels. Valuation is not stretched at roughly 19x trailing earnings and 12x EV/EBITDA, though the stock scores only 33rd percentile on the short score rank and trails peers like Eastman Chemical on both growth and momentum metrics.
The peer picture reinforces DuPont's relative resilience: correlated names AVNT, ESI, and PPG have all slipped 1–7% on the week, while DD has held its ground — a pattern consistent with its more diversified revenue mix. One note of caution: the ORTEX short score, while low at 37, actually eased sharply around July 23 when short interest dropped from roughly 5.7 million shares to just over 4 million in a single session, suggesting a technical covering event rather than a fundamental re-rating.
The August 4 print will test whether the Healthcare and Water momentum that has driven the year-to-date outperformance can offset any ongoing drag from the electronics and construction segments — and whether the margin profile that underpins the analyst consensus still holds.
See the live data behind this article on ORTEX.
Open DD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
Short sellers have quietly doubled down on DD in recent weeks — and the timing, three days before the May 21 earnings release, makes the move worth watching. The most striking signal is the pace of short-interest…
DuPont de Nemours heads into its May 7 Q1 print with an 8.6% weekly rally that sits sharply at odds with the rest of the chemicals sector. The divergence from peers is the sharpest data point in the setup. PPG fell…
